Neuronetics, Inc.

STIMNASDAQHealthcare● Active

$1.28

$-0.01(-0.78%)

Market Cap$89072384

P/E Ratio—

52W High$4.85

52W Low$0.8

Avg Volume2.4M

Open$1.28

Beta1.04

Free Cash Flow Financials Revenue

Neuronetics, Inc. (STIM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

STIM · free cash flow · updated Jun 8, 2026

Core FCF metrics

STIM · FCF · TTM · margin & CAGR

Free cash flow was −$21.2M for FY2025 (fiscal year ending 2025-12-31), up 34.8% year-over-year The FCF margin was -14.2%.

FY2025 Free Cash Flow−$21.2M▲ +34.8% YoY

Trailing 12M (TTM)−$13.6Mtrailing 4 quarters sum

FCF Margin-14.2%−$21.2M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

STIM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$20.4M(1M)−$21.2M▲ +34.8%-14.2%

FY2024−$31.0M(1M)−$32.5M▲ +5.7%-43.4%

FY2023−$32.0M(2M)−$34.4M▼ 1.2%-48.2%

FY2022−$30.7M(3M)−$34.0M▼ 12.1%-52.1%

FY2021−$28.0M(2M)−$30.3M▼ 4.2%-54.9%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

STIM · P/FCF · FCF yield · FCF per share

Neuronetics, Inc. (STIM) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

STIM · cash flow statement · operating / investing / financing

For FY2025, Neuronetics, Inc. generated −$20.4M in operating cash flow and spent 1M in capital expenditures, yielding −$21.2M in free cash flow.

Operating Activities

−$20.4M

Cash from core business operations

2025-12-31

Investing Activities

−$0.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$35.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$20.4M) − |CapEx| (1M) = FCF (−$21.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

STIM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Neuronetics, Inc.YOU

STIM

−$21.2M+34.8%-14.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Neuronetics, Inc. (STIM) reported free cash flow of −$21.2M for FY2025 (fiscal year ending 2025-12-31), up 34.8% year-over-year. The FCF margin was -14.2%.

Neuronetics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 10 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

STIM free cash flow · 8 questions

Neuronetics, Inc. free cash flow was −$21.2M for FY2025, up 34.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$13.6M.

STIM free cash flowSTIM FCFSTIM FCF 2025STIM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Neuronetics, Inc. · Neuronetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026